All Updates

All Updates

icon
Filter
FDA approval
Abata Therapeutics receives IND clearance to begin Phase I trials for ABA-101 Treg cell therapy for multiple sclerosis
Precision Medicine
Jul 9, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jul 9, 2024

Abata Therapeutics receives IND clearance to begin Phase I trials for ABA-101 Treg cell therapy for multiple sclerosis

FDA approval

  • Abata Therapeutics has received Investigational New Drug (IND) clearance from the FDA for its first product candidate, ABA-101. The investigational new drug is aimed to help patients with progressive multiple sclerosis (MS).

  • ABA-101 is a patient-derived T cell receptor (TCR)-Treg cell therapy created specifically for patients with progressive MS who have imaging proof of ongoing inflammatory tissue injury and are human leukocyte antigen (HLA)-DRB1*15:01 positive, which is a major risk factor. The treatment works by genetically modifying a patient's regulatory T-cells (Tregs) so they can specifically recognize and react to immunogenic myelin fragments in the CNS. 

  • Abata Therapeutics focuses on developing targeted therapies for autoimmune and inflammatory diseases using regulatory Treg technology. The company’s lead programs include treatments for progressive multiple sclerosis, type 1 diabetes, and inclusion body myositis. Its technology leverages Tregs to infiltrate, disrupt, and suppress inflammation at the disease site, offering targeted delivery.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.